Total Payments
$668,127
2024 Payments
$157,880
Companies
4
Transactions
84
Medicare Patients
1,510
Medicare Billing
$153,475
Payment Breakdown by Category
Other$662,677 (99.2%)
Travel$3,870 (0.6%)
Food & Beverage$1,581 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $662,677 | 21 | 99.2% |
| Travel and Lodging | $3,870 | 4 | 0.6% |
| Food and Beverage | $1,581 | 59 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $667,538 | 32 | $0 (2024) |
| Rochester Medical Corporation | $377.65 | 34 | $0 (2022) |
| C. R. Bard, Inc. & Subsidiaries | $184.35 | 16 | $0 (2023) |
| Becton, Dickinson and Company | $27.07 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $157,880 | 17 | UROGEN PHARMA, INC. ($157,853) |
| 2023 | $188,077 | 21 | UroGen Pharma, Inc. ($187,892) |
| 2022 | $127,003 | 41 | UroGen Pharma, Inc. ($126,625) |
| 2021 | $195,168 | 5 | UROGEN PHARMA, INC. ($195,168) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | UROGEN PHARMA, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $13,885.87 | General |
| 09/13/2024 | UROGEN PHARMA, INC. | — | Travel and Lodging | In-kind items and services | $2,303.96 | General |
| 09/13/2024 | UROGEN PHARMA, INC. | — | Travel and Lodging | In-kind items and services | $1,155.23 | General |
| 09/13/2024 | UROGEN PHARMA, INC. | — | Travel and Lodging | In-kind items and services | $201.96 | General |
| 09/12/2024 | UROGEN PHARMA, INC. | — | Travel and Lodging | In-kind items and services | $208.51 | General |
| 08/06/2024 | UROGEN PHARMA, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Dividend, profit or other return on investment | $99,900.00 | General |
| 07/05/2024 | Becton, Dickinson and Company | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Urology | ||||||
| 07/01/2024 | UROGEN PHARMA, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $13,125.00 | General |
| 06/13/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $320.15 | General |
| Category: UROTHELIAL CANCER | ||||||
| 06/13/2024 | UROGEN PHARMA, INC. | — | Food and Beverage | In-kind items and services | $151.34 | General |
| 05/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $83.33 | General |
| Category: UROTHELIAL CANCER | ||||||
| 04/22/2024 | Becton, Dickinson and Company | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Urology | ||||||
| 04/01/2024 | UROGEN PHARMA, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $13,125.00 | General |
| 03/01/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: UROTHELIAL CANCER | ||||||
| 02/28/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $157.63 | General |
| Category: UROTHELIAL CANCER | ||||||
| 02/28/2024 | UROGEN PHARMA, INC. | — | Food and Beverage | Cash or cash equivalent | $84.16 | General |
| 01/01/2024 | UROGEN PHARMA, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $13,125.00 | General |
| 10/01/2023 | UroGen Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $14,972.83 | General |
| 09/07/2023 | UroGen Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Dividend, profit or other return on investment | $141,500.00 | General |
| 07/01/2023 | UroGen Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $15,625.00 | General |
| 06/09/2023 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Urology | ||||||
| 06/07/2023 | UroGen Pharma, Inc. | — | Food and Beverage | In-kind items and services | $169.39 | General |
| 05/12/2023 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: Urology | ||||||
| 05/11/2023 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $8.44 | General |
| Category: Urology | ||||||
| 04/20/2023 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 342 | 487 | $446,019 | $29,244 |
| 2022 | 5 | 351 | 589 | $783,131 | $42,582 |
| 2021 | 5 | 379 | 617 | $733,838 | $43,156 |
| 2020 | 8 | 438 | 632 | $679,468 | $38,492 |
Total Patients
1,510
Total Services
2,325
Medicare Billing
$153,475
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 203 | 279 | $98,766 | $12,249 | 12.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 69 | $278,622 | $9,153 | 3.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 54 | 54 | $58,590 | $7,015 | 12.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 18 | $4,551 | $441.98 | 9.7% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 22 | 27 | $4,050 | $249.24 | 6.2% |
| 81002 | Urinalysis, manual test | Office | 2023 | 40 | 40 | $1,440 | $136.40 | 9.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 22 | 150 | $605,700 | $20,776 | 3.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 226 | 309 | $109,386 | $13,693 | 12.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $50,995 | $6,522 | 12.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 22 | 46 | $11,500 | $1,268 | 11.0% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 34 | 37 | $5,550 | $323.37 | 5.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 22 | 133 | $537,054 | $18,779 | 3.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 230 | 331 | $117,174 | $14,856 | 12.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 56 | 56 | $60,760 | $7,955 | 13.1% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 23 | 43 | $10,750 | $1,090 | 10.1% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2021 | 48 | 54 | $8,100 | $477.05 | 5.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 18 | 127 | $512,826 | $21,876 | 4.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 185 | 232 | $82,128 | $7,272 | 8.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 40 | 40 | $43,400 | $5,367 | 12.4% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2020 | 11 | 13 | $14,625 | $2,090 | 14.3% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 17 | 40 | $15,360 | $1,024 | 6.7% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2020 | 43 | 47 | $7,064 | $403.43 | 5.7% |
| 81000 | Manual urinalysis test with examination using microscope | Office | 2020 | 70 | 74 | $2,590 | $290.21 | 11.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 54 | 59 | $1,475 | $169.09 | 11.5% |
About Stuart Holden
Stuart Holden is a Urology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013941483.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Stuart Holden has received a total of $668,127 in payments from pharmaceutical and medical device companies, with $157,880 received in 2024. These payments were reported across 84 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($662,677).
As a Medicare-enrolled provider, Holden has provided services to 1,510 Medicare beneficiaries, totaling 2,325 services with total Medicare billing of $153,475. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Los Angeles, CA
- Active Since 07/10/2006
- Last Updated 01/08/2020
- Taxonomy Code 208800000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013941483
Products in Payments
- JELMYTO (Drug) $586.91
- Bard Urinary Drainage Bag (Device) $211.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Los Angeles
Mihir Desai, M.d, M.D
Urology — Payments: $1.6M
Urology $1.6M
Arie Belldegrun, Md, MD
Urology — Payments: $1.3M
Urology $1.3M
Dr. William Aronson, Md, MD
Urology — Payments: $753,306
Urology $753,306
Dr. Siamak Daneshmand, M.d, M.D
Urology — Payments: $317,876
Urology $317,876
Dr. Jeffrey Loh-Doyle, M.d, M.D
Urology — Payments: $295,721
Urology $295,721
Amir Lebastchi, Md, MD
Urology — Payments: $286,921
Urology $286,921